Expanded approval granted by Boston Scientific for long-term atrial fibrillation treatment
Boston Scientific's electrophysiology business has seen triple-digit growth, propelled by the success of its Farapulse pulsed field ablation (PFA) system. Two significant clinical trials, the ADVANTAGE-AF trial and the ReMATCH IDE clinical trial, are currently underway, exploring the safety and effectiveness of Farapulse in treating persistent atrial fibrillation (AFib).
The ADVANTAGE-AF Trial
The ADVANTAGE-AF trial, a prospective, single-arm study, enrolled 260 patients with drug-refractory, symptomatic persistent AFib lasting at least seven days. Conducted at 43 global sites, it demonstrated that 81% of treated patients showed no symptomatic arrhythmia recurrence after 12 months. The trial met its primary safety and effectiveness endpoints and was instrumental in securing FDA expanded approval for Farapulse's use in persistent AFib. Data from the trial were presented at the 2025 AF Symposium and recently published in the Journal of the American College of Cardiology.
The ReMATCH IDE Clinical Trial
The ReMATCH IDE clinical trial is an ongoing study designed to evaluate the safety and effectiveness of the Farawave PFA catheter for posterior wall ablation and pulmonary vein isolation in patients with persistent AFib who have undergone prior ablation procedures. It plans to enroll approximately 375 patients in the U.S. and Asia and aims to address treatment in more complex cases, including redo ablations.
Boston Scientific received expanded FDA approval in July 2025 to treat patients with symptomatic, drug-resistant persistent AFib using both the Farawave and Farawave NAV PFA catheters, broadening patient eligibility beyond the initial 2024 approval which was limited to paroxysmal AFib.
The company is also pursuing regulatory approvals in Europe, Japan, and China for these expanded indications in the coming months.
Summary of Key Clinical Trials
| Trial Name | Patient Population | Focus | Status/Outcome | |-----------------|------------------------------------|---------------------------------------|------------------------------------------------| | ADVANTAGE-AF | Persistent, drug-refractory AFib | Safety and efficacy of Farapulse PFA | Phase one complete, met endpoints, supported FDA approval[1][4][5] | | ReMATCH IDE | Persistent AFib with prior ablation | Posterior wall and pulmonary vein ablation | Ongoing, enrolling ~375 patients in US and Asia[2] |
These trials represent the forefront of Boston Scientific's clinical evidence supporting Farapulse's use in persistent AFib treatment.
According to Brad Sutton, Boston Scientific's chief medical officer for AF Solutions, these trials aim to further shape the future of AF treatment with safe and effective ablation technologies. PFA devices, like the Farapulse system, are changing the landscape of AFib treatment, and the next wave could grow the market further.
The ReMATCH IDE trial will also assess the adjunctive use of the Farapoint catheter for cavotricuspid isthmus ablation and left atrial ablation of the mitral isthmus in the same patient population. Boston Scientific expects to receive the CE mark for Europe as well as approval in Japan and China in the coming months.
In persistent AFib, the abnormal heart rhythm continues for at least seven days. The approach of PFA differs from other cardiac ablation techniques that apply either heat or extreme cold to create small scars to block AFib's irregular heartbeats. Instead, PFA uses nonthermal energy to correct the electrical signals causing the heart to beat inefficiently.
References:
- Boston Scientific Press Release
- ClinicalTrials.gov
- Journal of the American College of Cardiology
- Heart Rhythm
- AF Symposium 2025
- The ADVANTAGE-AF trial, a significant study on Boston Scientific's Farapulse pulsed field ablation system, showed promising results in treating drug-refractory, persistent atrial fibrillation (AFib), with 81% of treated patients experiencing no symptomatic arrhythmia recurrence after 12 months.
- The Food and Drug Administration (FDA) expanded its approval for Farapulse's use in persistent AFib, based on data from the ADVANTAGE-AF trial, which was instrumental in securing the approval.
- The ReMATCH IDE clinical trial is currently underway, focusing on the safety and effectiveness of Boston Scientific's Farawave PFA catheter for posterior wall ablation and pulmonary vein isolation in patients with persistent AFib who have undergone prior ablation procedures.
- The ReMATCH IDE trial also aims to assess the adjunctive use of the Farapoint catheter for cavotricuspid isthmus ablation and left atrial ablation of the mitral isthmus in the same patient population, with expected regulatory approvals in Europe, Japan, and China in the coming months.
- In medical-related fields, science and technology are evolving, with advancements in medtech, AI, and health-and-wellness analytics providing new tools for managing medical-conditions like persistent AFib.
- The success of Boston Scientific's Farapulse pulsed field ablation system, demonstrated in trials like ADVANTAGE-AF and ReMATCH IDE, is revolutionizing the treatment landscape for atrial fibrillation (AFib), offering hope for a safer and more effective approach to this common health concern.
